Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price target from $40 to $45.
Vertex’s Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs
Vertex Pharmaceuticals' cystic fibrosis treatment with vanza triple therapy. SKYLINE trials show non-inferiority to Trikafta, emphasizing once-daily dosing benefits.
